Want to see YDES full AI Analyst Report?
Top Page
YD Bio Limited
(NASDAQ:YDES)
Select Model
Select Model
Rating:47Neutral
Price Target:
$7.50
▲(111.86% Upside)
Action:Reiterated
Date:09/30/26
The score is primarily constrained by weak financial performance—worsening losses, persistent and accelerating cash burn, and negative equity in 2025—indicating elevated funding and balance-sheet risk. Technicals provide some support due to strong trend above major moving averages, but overbought signals temper that positive. Valuation remains challenged because losses (negative P/E) reduce confidence in conventional valuation measures.
Positive Factors
Low Debt Burden
Very low reported debt limits refinancing pressure and interest expense, preserving more flexibility for research, product development, and operations. This is a meaningful structural support because the company is loss-making and therefore benefits from avoiding additional fixed financial obligations.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow shows that the business is not yet self-funding its operations. Accelerating burn can increase dependence on external capital, restrict investment choices, and raise liquidity risk if financing access becomes less favorable over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Debt Burden
Very low reported debt limits refinancing pressure and interest expense, preserving more flexibility for research, product development, and operations. This is a meaningful structural support because the company is loss-making and therefore benefits from avoiding additional fixed financial obligations.
Read all positive factors
YD Bio Limited (YDES) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$539.11M
Dividend YieldN/A
Average Volume (3M)493.98K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,842,840
10 Day Avg. Volume821,291
30 Day Avg. Volume493,983
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)-284.80
Price to Sales (P/S)1362.74
P/FCF Ratio-101.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
YD Bio Limited Business Overview & Revenue Model
Company Description
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of whi...
YD Bio Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 596.82K | 510.36K | 350.13K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -42.15K | 155.36K | 153.44K | 0.00 | 0.00 |
| EBITDA | -2.99M | -8.10M | -1.28M | 22.25K | 3.79M | 8.70M |
| Net Income | -2.97M | -8.31M | -1.41M | 13.56K | 3.79M | 8.70M |
Balance Sheet | ||||||
| Total Assets | 2.95M | 13.78M | 6.86M | 321.21K | 17.93M | 118.06M |
| Cash, Cash Equivalents and Short-Term Investments | 6.31K | 6.01M | 3.13M | 87.10K | 14.13K | 5.40K |
| Total Debt | 0.00 | 6.76K | 22.55K | 47.58K | 0.00 | 0.00 |
| Total Liabilities | 19.00M | 16.64M | 273.98K | 298.22K | 6.74M | 9.11M |
| Stockholders Equity | -16.05M | -2.86M | 6.59M | 22.99K | 11.20M | 108.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | -8.04M | -4.75M | -55.95K | -3.02M | -688.42K |
| Operating Cash Flow | -1.18M | -6.60M | -1.84M | -55.66K | -3.02M | -688.41K |
| Investing Cash Flow | 7.95M | -1.44M | -2.90M | -290.00 | 100.38M | -1.15M |
| Financing Cash Flow | -6.81M | 10.87M | 7.73M | 113.89K | -97.34M | 1.15M |
YD Bio Limited Technical Analysis
Positive
3.54
Price Trends
3.60
Positive
3.41
Positive
6.18
Positive
Market Momentum
0.80
Negative
74.84
Negative
93.81
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YDES, the sentiment is Positive. The current price of 3.54 is below the 20-day moving average (MA) of 4.31, below the 50-day MA of 3.60, and below the 200-day MA of 6.18, indicating a bullish trend. The MACD of 0.80 indicates Negative momentum. The RSI at 74.84 is Negative, neither overbought nor oversold. The STOCH value of 93.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for YDES.
YD Bio Limited Risk Analysis
YD Bio Limited disclosed 61 risk factors in its most recent earnings report. YD Bio Limited reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
YD Bio Limited Peers Comparison
UnderperformOutperform
Sector (51)
YDES
YD Bio Limited
7.42
-10.50
-58.59%
SCNI
Scinai Immunotherapeutics
1.42
-12.48
-89.78%
ADTX
Aditxt
0.04
-18,354.78
-100.00%
SPRC
SciSparc Ltd.
4.72
-49.55
-91.30%
CDT
CDT Equity
1.36
-34,698.64
-100.00%
VRAX
Virax Biolabs Group Ltd. Class A
2.18
-13.30
-85.89%
YD Bio Limited Corporate Events
YD Bio Files First-Half 2026 Results, Reports Improved Equity Position
Sep 1, 2026
YD Bio Limited has filed its unaudited interim consolidated financial statements for the six months ended June 30, 2026, showing total assets of about $10.1 million and a swing in shareholders’ equity from a deficit of $2.9 million at year-e...
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem
Aug 11, 2026
On August 11, 2026, YD Bio Limited launched two chrono-nutrition nutraceutical products in Taiwan as part of a new physician-partnership initiative with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. The daytime...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.